 Greater than 75 relative reduction in liver fat content achieved at the 1.8 mg and 2.4 mg doses at 24 weeks Significant reductions in serum alanine aminotransferase ALT and corrected T1 cT1 observed, both established markers of liver inflammation Mean weight loss of 7.2 placebo adjusted 6.0 in subjects without diabetes at the 1.8 mg ... The post Altimmune Announces Positive Topline Results from 24-Week 12-Week Extension Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver D... 